Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Journal of Translational Medicine|June 20, 2024
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIsLige Wu, Zihua Zou, Yan Li, et al.
Expert Review of Anticancer Therapy|March 25, 2024
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencingZiyi Xu, Yan Li, Lin Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|April 5, 2017
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutationsYan Zhang, Zheng Wang, Xuezhi Hao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 12, 2013
[Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance]Bin Wang, Xin Zhang, Lin Lin, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 12, 2013
[Treatment choice for advanced non-small cell lung cancer patients who had gradual progression after EGFR-TKIs: 32 cases report]Lin Lin, Bin Wang, Xuezhi Hao, et al.
Thoracic Cancer|May 12, 2025
A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLCHanqi Yuan, Zihua Zou, Xuezhi Hao, et al.
Thoracic Cancer|January 15, 2016
Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancerJianliang Yang, Yuankai Shi, Xiangru Zhang, et al.
Thoracic Cancer|September 19, 2017
Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective studyShufei Yu, Yan Wang, Junling Li, et al.
Frontiers in Oncology|September 20, 2021
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical OutcomesHaiyan Xu, Guangjian Yang, Weihua Li, et al.
Thoracic Cancer|March 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung AdenocarcinomaLige Wu, Zihua Zou, Yan Li, et al.
Pageof 11